Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 20/20 | 0.65 |
| ▸ | THRB | P10828 | 6/20 | 0.59 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5235790 | 0.94 | TGFBR1 (0.56) | TGFBR1THRBMAPK14 | |
| SCHEMBL411689 | 0.84 | TGFBR1 (0.71) | TGFBR1THRBMAPK14 | |
| SCHEMBL29832035 | 0.83 | TGFBR1 (0.78) | TGFBR1THRBMAPK14 | |
| SCHEMBL409531 | 0.80 | TGFBR1 (0.74) | TGFBR1THRBMAPK14 | |
| SCHEMBL412882 | 0.80 | TGFBR1 (0.70) | TGFBR1THRBMAPK14 | |
| SCHEMBL372373 | 0.79 | TGFBR1 (1.00) | TGFBR1THRBMAPK14 | |
| SCHEMBL411832 | 0.78 | TGFBR1 (0.72) | TGFBR1THRBMAPK14 | |
| SCHEMBL4471552 | 0.78 | TGFBR1 (0.52) | TGFBR1THRBMAPK14 | |
| SCHEMBL373954 | 0.77 | TGFBR1 (0.75) | TGFBR1THRBMAPK14 | |
| SCHEMBL5240634 | 0.77 | TGFBR1 (0.75) | TGFBR1THRBMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1397364-B1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | LILLY CO ELI (US) | 2007-07-25 | — | — | EP | disclosed |
| EP-1397364-B1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | LILLY CO ELI (US) | 2007-07-25 | — | — | EP | disclosed |
| US-7087626-B2 | Pyrrole derivatives as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2006-08-08 | — | — | US | disclosed |
| US-20040106604-A1 | Novel pyrrole derivatives as pharmaceutical agents | ELI LILLY AND COMPANY | 2004-06-03 | — | — | US | disclosed |
| EP-1397364-A1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002094833-A1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106604-A1 | Novel pyrrole derivatives as pharmaceutical agents | TGFBR1, SMAD3, TGFBR2 | TGFBR1 1/4885THRB 500/4885MAPK14 546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.